Aspirin not helpful in stopping dementia


In the last number of Neurology®, a team representing the Aspirin in Reducing Events in the Elderly (ASPREE) study reports the cognitive outcomes from low-dose aspirin (100 mg/d) therapy vs placebo in elderly individuals who were free of cardiovascular disease, physical disability, or diagnosed dementia.

The trial enrolled 19,114 persons and followed them for a median of 4.7 years.

Aspirin therapy did not reduce the number of cases of incident mild cognitive impairment or dementia nor benefit cognition.